the aid library

LIST OPTIONS

Filter

5143

Antiepileptic drug therapy in individuals with intellectual disability & epilepsy

World Health Organization (2012) C_WHO

Q12: Should the treatment be similar in individuals with intellectual disability and epilepsy compared to people with epilepsy only?

External Link

The path that ends AIDS: UNAIDS Global AIDS Update 2023
recommended

UN Children's Fund UNICEF (2023) CC

This report makes clear that there is a path to end AIDS. Taking that path will help ensure preparedness to address other pandemic challenges, and advance progress across the Sustainable Development Goals. The data and real-world examples in the report make it very clear what that path is. It is not... more

Download (395)

View PDF (542)

Trastorno por déficit de atención con hiperactividad

T. S. Moriyama; A. J. M. Cho; R. E. Verin; et al. IACAPAP (2017) C2

Trastornos externalizantes Capítulo D.1 Edición: Matías Irarrázaval & Andrés Martín Traducción: Fernanda Prieto Tagle, Marta García Acuña

Download (500)

View PDF (700)

Community Ear & Hearing Health - Volume 9 • Issue 12 (2012)

Community Ear & Hearing Health (2012) C2

This journal is funded by CBM

Download (513)

View PDF (733)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (637)

View PDF (825)

Interim National Guidelines for Monkeypox Outbreak Response

Federal Ministry of Health - Nigeria Centre for Disease Contro (2017) C2

This document provides information and recommendations for action, based on the current available knowledge around monkeypox. It is a first draft which will be updated in light of evolving evidence and additional information as they become available.

Download (638)

View PDF (895)

India: Guidelines for the Public Private Partnership Model of ART centres

National AIDS Control Organisation (NACO), Government of India (2017) C1

Download (1176)

View PDF (2639)

Caring for Newborns and Children in the Community. Facilitator Notes

World Health Organization; UNICEF (2011) C_WHO

Treat diarrhoea, confirmed malaria, and fast breathing

Download (987)

View PDF (1411)

Additional Content to the National Sexually Transmitted Infections Care and Treatment Course for Health Care Workers

Dept. of Health, Republic of South Africa (2015) C1

High Transmission Areas: Key Populations

Download (369)

View PDF (470)

WHO technical consultation on oxygen access scale-up for COVID-19

World Health Organization WHO (2021) C_WHO

Download (715)

View PDF (1264)

Generic risk assessment model for insecticide-treated nets, 2nd ed.

World Health Organization (WHO) (2018) C_WHO

Long-lasting insecticidal nets (LNs) constitute a core vector control intervention against malaria. A number of new LN products are under development and will require assessment of risks to humans. This document provides an updated generic model that can be used for the risk assessment of exposure t... more

Download (464)

View PDF (561)

Module de formation aux services DE FAUTEUILS ROULANTS - NIVEAU ÉLÉMENTAIRE (Manuel de référence)

World Health Organization (WHO) (2012) C_WHO

The main purpose of the training package is to develop the minimum skills and knowledge required by personnel involved in wheelchair service delivery. An important aim of the training package is to get it integrated into the regular paramedical/rehabilitation training programs such as physiotherapy,... more

Download (548)

View PDF (489)

HIV and AIDS in India

Avert (2018) C2

Download (1123)

View PDF (2406)

Technical note for Ebola virus disease preparedness planning for entry screening at airports, ports and land crossings

World Health Organization (2014)

Download (412)

View PDF (456)

Rules of engagement between the UN and private actors - Towards a regulatory and institutional framework

Jens Martens and Karolin Seitz MSEREOR, Brot für die Welt, Global Policy Forum Europe (2019) C2

This working paper aims to provide a rough over-view of existing rules and guidelines on the coopera-tion between the UN and the private sector – at least as they are publicly available. It will describe com-mon features and discuss advances and shortcomings of the most prominent a... more

Download (403)

View PDF (559)

Six concrete measures to support women and girls in all their diversity in the context of the COVID-19 pandemic

UNAIDS (2020) C_WHO

The report underscores that sexual and reproductive health and rights are often the first to be sacrificed during epidemics and that the gains of the past decade must be protected. The report also makes it clear that scarce resources must be focused on the most marginalized women and girls, includin... more

Download (276)

View PDF (286)

Informe Semanal n° 36 de Evidências sobre Variantes de Atenção de SARS-CoV-2 — Português (Brasil)

Ministério da Saúde, Brasil (2021) C2

O Informe Semanal de Evidências sobre Variantes de Atenção do SARS-CoV-2 é uma produção organizada pelo Departamento de Ciência e Tecnologia da Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde do Ministério da Saúde (DECIT/SCTIE/MS). O documento tem o objetiv... more